AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1934433 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia and reperfusion (Hôpital Lariboisière protocol)
Number of subjects: 33
Study 1934433 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia with allopurinol enriched blood reperfusion (Hôpital Broussais protocol)
Number of subjects: 33
Study 1934433 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia with unmodified blood reperfusion (control group)
Number of subjects: 33
Study 7211735 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined liquid diets
Number of subjects: 10
Study 7211735 — intervention group
Group type: COMPARATOR
Intervention: Free-choice diet
Number of subjects: 10
Study 31004340 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) combined with pharmacotherapy (alpha-blocker, anti-inflammatory agent, muscle relaxant, short course of antibiotic)
Number of subjects: 31
Study 31004340 — intervention group
Group type: COMPARATOR
Intervention: Sham-ESWT combined with pharmacotherapy
Number of subjects: 31
Study 31325474 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual food stimuli presented as first targets in a rapid stream of pictures
Number of subjects: 103
Study 31325474 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual food stimuli presented as second targets
Number of subjects: 103
Study 31325474 — intervention group
Group type: EXPERIMENTAL
Intervention: Task irrelevant food distractors
Number of subjects: 103
Study 28715586 — intervention group
Group type: EXPERIMENTAL
Intervention: Iris-claw intraocular lens (IC‐IOL) implantation
Number of subjects: 390
Study 28715586 — intervention group
Group type: COMPARATOR
Intervention: Scleral-fixated posterior chamber intraocular lens (SF‐PCIOL) implantation
Number of subjects: 390
Study 31149084 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 113
Study 31149084 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 113
Study 31149084 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 113
Study 31149084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 113
Study 31149084 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 113
Study 31149084 — intervention group
Group type: EXPERIMENTAL
Intervention: All neuroleptics
Number of subjects: 113
Study 23857036 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 36
Study 23857036 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MIT)
Number of subjects: 36
Study 22633423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS) containing 500 IU/mL thrombin and synthetic aprotinin
Number of subjects: 140
Study 22633423 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (control)
Number of subjects: 140
Study 22633423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 140
Study 19668789 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) in 2004-2005 cohort
Number of subjects: 243
Study 19668789 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis in 1999-2000 cohort
Number of subjects: 243
Study 19668789 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI in 2004-2005 cohort
Number of subjects: 243
Study 17678487 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 17678487 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous carotid angioplasty and stenting
Number of subjects: 0
Study 17678487 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet agents (i.e., clopidogrel)
Number of subjects: 0
Study 17678487 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol-lowering agents (i.e., statins)
Number of subjects: 0
Study 17678487 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 15130870 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive (80% cued)
Number of subjects: 18
Study 15130870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpredictive (50% cued)
Number of subjects: 18
Study 15130870 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipredictive (20% cued)
Number of subjects: 18
Study 12182769 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 46
Study 12182769 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 46
Study 10322740 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (34 patients)
Number of subjects: 61
Study 10322740 — intervention group
Group type: COMPARATOR
Intervention: Control group (27 patients)
Number of subjects: 61
Study 7647725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollinex (Bencard)
Number of subjects: 27
Study 7647725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2796617 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine 10 mg in hyperbaric solution
Number of subjects: 102
Study 2796617 — intervention group
Group type: COMPARATOR
Intervention: 0.5% tetracaine 10 mg in isobaric solution
Number of subjects: 102
Study 356246 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren, 25 mg t.i.d.)
Number of subjects: 109
Study 356246 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg t.i.d.)
Number of subjects: 109
Study 31317388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 0
Study 30315687 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically guided transversus abdominis plane block (LTAP) with bupivacaine
Number of subjects: 70
Study 30315687 — intervention group
Group type: EXPERIMENTAL
Intervention: Port-site local anaesthetic infiltration (LAI) with bupivacaine
Number of subjects: 70
Study 30315687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27781388 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) practices in Turkey
Number of subjects: 66711
Study 25892170 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional help sheet (intervention group, n=34)
Number of subjects: 65
Study 25892170 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (n=31)
Number of subjects: 65
Study 22438297 — intervention group
Group type: EXPERIMENTAL
Intervention: III + ISG
Number of subjects: 31
Study 22438297 — intervention group
Group type: COMPARATOR
Intervention: III only
Number of subjects: 31
Study 20820817 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 500 mg orally twice a day for 28 days
Number of subjects: 65
Study 20820817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 19634958 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 150
Study 19634958 — intervention group
Group type: COMPARATOR
Intervention: Educational control intervention
Number of subjects: 150
Study 17869297 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection in saline
Number of subjects: 238
Study 17869297 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral prostate resection
Number of subjects: 238
Study 17869297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 238
Study 15231445 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression (MD)
Number of subjects: 15
Study 15231445 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 15
Study 11509491 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine patch (14 patients)
Number of subjects: 26
Study 11509491 — intervention group
Group type: COMPARATOR
Intervention: Transdermal placebo (12 patients)
Number of subjects: 26
Study 9269880 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reinforcement for decreases in high-preference sedentary activity
Number of subjects: 34
Study 9269880 — intervention group
Group type: EXPERIMENTAL
Intervention: Punishment for high-preference sedentary activity
Number of subjects: 34
Study 9269880 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to high-preference sedentary activity restricted
Number of subjects: 34
Study 9269880 — intervention group
Group type: COMPARATOR
Intervention: No contingencies on activity (control group)
Number of subjects: 34
Study 8111799 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 10.0, 20.0, or 40.0 mg, or 20 mg plus 12.5 mg hydrochlorothiazide (HCTZ) given once daily
Number of subjects: 256
Study 8111799 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg quinapril daily or 20 mg quinapril plus 12.5 mg HCTZ daily
Number of subjects: 256
Study 8111799 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 256
Study 3739802 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control skills intervention
Number of subjects: 0
Study 3739802 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo condition (discussion-oriented intervention)
Number of subjects: 0
Study 3739802 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 30908867 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (Fitbit Zip, step goals, 1 phone call/month for 6 months)
Number of subjects: 43
Study 30908867 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy (control group)
Number of subjects: 43
Study 29857989 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional RBC materials
Number of subjects: 32
Study 29857989 — intervention group
Group type: EXPERIMENTAL
Intervention: Admira Fusion and Admira Fusion x‐tra
Number of subjects: 32
Study 29857989 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified RBC restoration protocol
Number of subjects: 32
Study 27129491 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision (piezo-assisted orthodontics)
Number of subjects: 24
Study 27129491 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthodontics (Control)
Number of subjects: 24
Study 25233644 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Lianquan (CV 23)
Number of subjects: 180
Study 25233644 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at Hegu (LI 4) and Neiguan (PC 6)
Number of subjects: 180
Study 25233644 — intervention group
Group type: COMPARATOR
Intervention: Swallowing rehabilitation training
Number of subjects: 180
Study 23786716 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention (RESTORE)
Number of subjects: 125
Study 23786716 — intervention group
Group type: COMPARATOR
Intervention: Leaflet comparator (Macmillan Cancer Backup, Coping with Fatigue)
Number of subjects: 125
Study 20801782 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 200 mg twice daily
Number of subjects: 1130
Study 20801782 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1130
Study 18684410 — intervention group
Group type: EXPERIMENTAL
Intervention: Research team training program
Number of subjects: 0
Study 11904596 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 247
Study 11904596 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive
Number of subjects: 247
Study 11904596 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 247
Study 10622088 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (group A: 26 patients)
Number of subjects: 128
Study 10622088 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (group A: 18 patients)
Number of subjects: 128
Study 10622088 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (group B: 36 patients)
Number of subjects: 128
Study 10622088 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (group B: 48 patients)
Number of subjects: 128
Study 7962459 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 followed by a prostaglandin analogue (PG)
Number of subjects: 20000
Study 7962459 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 followed by 400 micrograms of misoprostol (PGE1 analogue)
Number of subjects: 20000
Study 2682025 — intervention group
Group type: COMPARATOR
Intervention: Triiodothyronine administration at the end of operation and during the initial 24 hours after operation (study I)
Number of subjects: 2
Study 2682025 — intervention group
Group type: COMPARATOR
Intervention: Triiodothyronine administration (study II)
Number of subjects: 2
Study 180405 — intervention group
Group type: COMPARATOR
Intervention: High dosage intermittent polychemotherapy, given as 3 infusions at intervals of a week for 3 years.
Number of subjects: 126
Study 31944580 — intervention group
Group type: EXPERIMENTAL
Intervention: suvorexant 10 mg (could be increased to 20 mg based on clinical response)
Number of subjects: 285
Study 31944580 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 285
Study 31944580 — intervention group
Group type: EXPERIMENTAL
Intervention: suvorexant
Number of subjects: 285
Study 27823800 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin 1000 μg once daily for 27 months
Number of subjects: 271
Study 27823800 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets once daily for 27 months
Number of subjects: 271
Study 27823800 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin 1000 μg
Number of subjects: 271
Study 27823800 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 271
Study 26056336 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment SBP ≤130 mm Hg
Number of subjects: 8831
Study 26056336 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment SBP 131 to 141 mm Hg
Number of subjects: 8831
Study 26056336 — intervention group
Group type: COMPARATOR
Intervention: In-treatment SBP ≥142 mm Hg
Number of subjects: 8831
Study 23573189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 189
Study 23573189 — intervention group
Group type: COMPARATOR
Intervention: Dual energy X-ray absorptiometry (DXA)
Number of subjects: 189
Study 20619924 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual low dose chest CT scans (CT group)
Number of subjects: 4104
Study 20619924 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 4104
Study 19572228 — intervention group
Group type: EXPERIMENTAL
Intervention: human follicle stimulating hormone (hFSH)
Number of subjects: 401
Study 19572228 — intervention group
Group type: COMPARATOR
Intervention: recombinant FSH (rFSH)
Number of subjects: 401
Study 17098527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Loss (TL)
Number of subjects: 1404
Study 17098527 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Graft-Related Events (GRE)
Number of subjects: 1404
Study 17098527 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft-Related Events (GRE) during 1-year follow-up
Number of subjects: 1404
Study 17098527 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities (dialysis dependency, nonsmoking status, hypertension, increasing age)
Number of subjects: 1404
Study 15113814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg/d
Number of subjects: 319
Study 15113814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg/d
Number of subjects: 319
Study 15113814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 90 mg/d
Number of subjects: 319
Study 15113814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 15113814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (all doses)
Number of subjects: 319
Study 15113814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (in patients with renal dysfunction or severe systemic congestion)
Number of subjects: 319
Study 11353629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular quinine dihydrochloride (20 mg/kg of body weight)
Number of subjects: 120
Study 11353629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular quinine
Number of subjects: 120
Study 9150899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat, high carbohydrate diet
Number of subjects: 53
Study 9150899 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 53
Study 9150899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 53
Study 7960856 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and alternating air mattress
Number of subjects: 100
Study 7960856 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 100
Study 7960856 — intervention group
Group type: COMPARATOR
Intervention: Alternating air mattress alone
Number of subjects: 100
Study 7960856 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 100
Study 3500051 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate intravenous bolus test doses (50 mg/m2) with folinic acid (15 mg every 6 h)
Number of subjects: 0
Study 3500051 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate intravenous bolus test doses (50 mg/m2) without folinic acid
Number of subjects: 0
Study 3500051 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 h infusion of methotrexate individualized to achieve a peak plasma concentration of 5 X 10(‐4) M
Number of subjects: 0
Study 31490549 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 367
Study 31490549 — intervention group
Group type: COMPARATOR
Intervention: p-IGF-1R/InsR-positive patients
Number of subjects: 367
Study 31490549 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsitinib
Number of subjects: 367
Study 31490549 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐1R stimulation
Number of subjects: 367
Study 31173410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen combined with amphotericin
Number of subjects: 30
Study 31173410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 30
Study 31173410 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen combined with fluconazole
Number of subjects: 30
Study 31173410 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen combined with flucytosine
Number of subjects: 30
Study 31173410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen combined with amphotericin and fluconazole
Number of subjects: 30
Study 28394730 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Load (CT)
Number of subjects: 76
Study 28394730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending Pyramidal Load (PR)
Number of subjects: 76
Study 28394730 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 76
Study 26238679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycogen(TM) -containing skin care product via sonophoresis
Number of subjects: 26
Study 26238679 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control group (skin care product without Lycogen(TM))
Number of subjects: 26
Study 23140916 — intervention group
Group type: EXPERIMENTAL
Intervention: NACP nanocomposite
Number of subjects: 25
Study 23140916 — intervention group
Group type: COMPARATOR
Intervention: Control composite
Number of subjects: 25
Study 22097111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial pressure monitoring
Number of subjects: 61
Study 22097111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intracranial pressure monitoring)
Number of subjects: 61
Study 19259830 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 50
Study 19259830 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 50
Study 16711308 — intervention group
Group type: EXPERIMENTAL
Intervention: Omental plugging (study group)
Number of subjects: 100
Study 16711308 — intervention group
Group type: COMPARATOR
Intervention: Omentopexy (control group)
Number of subjects: 100
Study 14757615 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 2110
Study 14757615 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 2110
Study 11496234 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (inhaled nitric oxide synthase inhibitor)
Number of subjects: 10
Study 11496234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11496234 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 10
Study 11496234 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen challenge
Number of subjects: 10
Study 9284163 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR at 10(8) CFU plus CVD 111 at 10(8), 10(7), or 10(6) CFU
Number of subjects: 298
Study 9284163 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 111 at 10(7) CFU
Number of subjects: 298
Study 9284163 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR at 10(9) CFU plus CVD 111 at 10(9) or 10(8) CFU
Number of subjects: 298
Study 9284163 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 111 at high dose
Number of subjects: 298
Study 9284163 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 111 at low dose
Number of subjects: 298
Study 9284163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 9284163 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 298
Study 9284163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent vaccine
Number of subjects: 298
Study 7970745 — intervention group
Group type: EXPERIMENTAL
Intervention: betaxolol (0.5%, 2 x 30 microliters)
Number of subjects: 10
Study 7970745 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 10
Study 3670970 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 42
Study 3670970 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 42
Study 29699748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 74
Study 29699748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous abciximab
Number of subjects: 74
Study 29699748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 26765630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Training Group (MG)
Number of subjects: 23